Letter from Chair
Greetings!
We are pleased to bring this section website to the Texas ACC, targeting providers and multidisciplinary trainees that take care of patients with de novo or chronic heart failure as well as cardiac transplantation and durable mechanical support. The proportion of patients with heart failure in the country is growing at an exponential pace. Importantly, we now stand at a unique intersection bearing witness to significant breakthroughs in guideline medical therapies as well as imaging modalities to phenotype and treat ischemic and non-ischemic cardiomyopathies. We have drug options for once-fatal disorders such as cardiac amyloidosis. We have updated algorithms on how best to recognize and manage cardiogenic shock. We have multiple, robust mechanical platforms to treat univentricular and biventricular failure. As a community, we pride ourselves in taking care of this vulnerable population and cherish each individual’s commitment to their care.
We are pleased to bring this section website to the Texas ACC, targeting providers and multidisciplinary trainees that take care of patients with de novo or chronic heart failure as well as cardiac transplantation and durable mechanical support. The proportion of patients with heart failure in the country is growing at an exponential pace. Importantly, we now stand at a unique intersection bearing witness to significant breakthroughs in guideline medical therapies as well as imaging modalities to phenotype and treat ischemic and non-ischemic cardiomyopathies. We have drug options for once-fatal disorders such as cardiac amyloidosis. We have updated algorithms on how best to recognize and manage cardiogenic shock. We have multiple, robust mechanical platforms to treat univentricular and biventricular failure. As a community, we pride ourselves in taking care of this vulnerable population and cherish each individual’s commitment to their care.
Mahwash Kassi, MD
Yevgeniy Khariton, MD, MEd, MSc